Member Info for Globalcrossings

RNS Number : 2096N D1 Oils Plc 08 June 2010   Tuesday, 8 June, 2010 D1 Oils plc ("D1 Oils" or the "Company") Offer update Further to its announcement of 6 May and that of Mission NewEnergy Limited ("Mission") of 25 May, the Board of D1 Oils confirms that detailed discussions are continuing regarding a possible recommended all share offer by Mission for the entire issued and to be issued share capital of D1 Oils. Indeed, Mission has recently met with shareholders of D1 Oils.   The Board is proceeding on the basis of an in principle agreement that Mission will offer, subject, inter alia, to the completion of mutual confirmatory due diligence, new Mission shares representing approximately £16 million of value at Mission's prevailing share price at the date of a firm offer announcement.  The Board also announced on 6 May that it was seeking to bring all offer discussions to a conclusion within two months and that if a firm offer or material new financing was not announceable by this time, the Board would conclude its ongoing strategic review.  This position remains unchanged and the Board is working with Mission and other interested parties towards this timeframe. Given the above, the entire Board remains strongly and unanimously of the view that business continuity and management certainty are needed at this time. The Board strongly recommends, in respect of the forthcoming general meeting on 14 June, that all D1 Oils shareholders who support the Board submit their BLUE proxy forms by post to arrive with Capita Registrars no later than 11.30 a.m. on Thursday 10 June, or vote electronically through CREST by no later than 11.30 a.m. on Saturday 12 June.  This announcement is being made without the agreement or approval of Mission. There can be no certainty that an offer will be made for the Company or the terms on which any such offer may be made.  A further announcement will be made in due course. For further information please contact:    D1 Oils plc + 44 (0) 20 7367 5609      Barclay Forrest, Chairman Piper Jaffray Ltd. + 44 (0) 20 3142 8700       Charlie Lilford Rupert Winckler (Qualified Executive) Brunswick Group + 44 (0) 20 7404 5959             Kevin Byram Tom Williams   Piper Jaffray Ltd., which is authorised and regulated by the Financial Services Authority, is acting exclusively for D1 Oils and for no-one else in connection with the matters referred to in this announcement and will not be responsible to anyone other than D1 Oils for providing the protections afforded to customers of Piper Jaffray Ltd. nor for giving advice in relation to the matters referred to in this announcement. Responsibility The Directors of D1 Oils accept responsibility for all of the information contained in this

RNS Number : 2016N Vectura Group plc 08 June 2010    Vectura Group plc ("The Company")   BLOCK LISTING APPLICATION     Chippenham, UK, 8 June 2010:Vectura Group plc (LSE: VEC) today announces that application has been made to the UK Listing Authority and the London Stock Exchange for a block listing of 1,500,000 ordinary shares of 0.025 pence each.   The application is in respect of shares to be issued in connection with the Vectura Group plc Share Incentive Plan and is in addition to the remaining shares approved but un-issued under existing block applications.   Additionally, under the Vectura Group plc Share Incentive Plan (an HMRC approved all-employee share purchase plan adopted by the Company's shareholders on 27 September 2006) (the "Plan"), Dr Christopher Blackwell and Anne Hyland, Executive Directors of the Company, as trustees of the Plan, become the non-beneficial holders of 1,500,000 Ordinary Shares of the Company, to be distributed to the employees of the Company under the Plan.    The Executive Directors of the Company have the following interests as a result of their personal participation in the Plan:   Free Shares awarded on  7 June 2010 at 38p per share Total number of  Free Shares and Matching Shares held in the Plan on 7 June 2010 Dr Christopher Blackwell 7,895 26,347 Anne Hyland 7,895 26,647   The beneficial ownership of the 7,895 Free Shares awarded under the Plan will pass to the Executive Directors on 7 June 2013, subject to their continued employment.       Enquiries: Vectura Group plc Anne Hyland Chief Financial Officer and Company Secretary Tel: 01249 667612           This information is provided by RNS The company news service from the London Stock Exchange   END     MSCKKODDABKDKAK

RNS Number : 2066N imJack PLC 07 June 2010    imJack plc   ("imJack" or "the Company")   Result of General Meeting Restoration of Trading Directors Shareholdings     The Board of imJack plc (AIM: IMJ), the digital educational secure networking business, is pleased to announce that, following a General Meeting of the Company held today, all resolutions (the "Resolutions") as set out in the recently published Circular to shareholders, were duly passed.   The Circular, which is available from the Company's website, www.imjack.com, and referred to in the announcement released on 20 May 2010, set out various proposals (the "Proposals"), including, inter alia, the following:   ·      Proposed placing of 71,333,333 ordinary shares of 1p each ("Ordinary Shares") at a placing price of 1.5 pence per share to raise £0.9 million net of expenses (of which 4,666,667 Ordinary Shares have been prepaid); ·      Issue of convertible loan stock to Jeffrey Morris, interim CEO, to raise £0.2 million; ·      Proposed acquisition of John Devonshire Connect Limited (a reseller to the education market)to be satisfied through the issue of 10,000,000 new Ordinary Shares; ·      Proposed acquisition of Tellbrook Limited (a company which owns the IP currently licensed by the Company) to be satisfied through the issue of 33,333,333 new Ordinary Shares; ·      Conversion of Directors' and other connected party loans into 75,074,176 new Ordinary Shares; ·      Conversion of debts owed to certain creditors into 2,000,000 new Ordinary Shares; ·      Approval of waiver of obligations under Rule 9 of the city Code on Takeovers and Mergers.   Application has been made to the London Stock Exchange for 191,740,842 new Ordinary Shares (the "New Ordinary Shares") to be admitted to trading on AIM ("Admission") in respect of the Proposals set out above which have today been completed following the passing of the Resolutions.   Restoration of trading on AIM and Admission of the New Ordinary Shares   Trading in the Company's Ordinary Shares on AIM was suspended on 11 January 2010 as a result of financial uncertainty of the Company. In addition, the Company has yet to publish its results for year ended 30 September 2009. The Company is pleased to announce that it intends to publish its results for the year ended 30 September 2009 tomorrow. Completion of the Proposals above together with publication of the Company's results means that the Directors believe that the Company now has sufficient working capital and that trading in the Company's Ordinary Shares on AIM should be restored. Accordingly application has been made to the London S

RNS Number : 1815N Medgenics Inc 07 June 2010    Medgenics, Inc. ('Medgenics' or the 'Company')   Statement re. Share Price Movement   Medgenics (AIM: MEDG and MEDU), the company that has developed a novel technology for the manufacture and delivery of therapeutic proteins continuously in patients using their own tissue, has noted the significant share price movement and recent press coverage in both the MEDU and MEDG quotes.   The Company confirms that it is not aware of any unpublished price sensitive information or of any other reason for the recent share price movements.   For further information, contact:   Andrew Pearlman                                              +972 4 902 8900 CEO Medgenics, Inc   Mike Wort / Anna Dunphy                                 +44 207 861 3838 De Facto Communications (PR)   James Pinner / Derek Crowhurst                        +44 207 444 0800 Religare Capital Markets (Nomad)                       Ian Callaway / Alex Mattey                               +44 207 638 5600 SVS Securities plc (Joint Broker)   Jonathan Senior                                                 +44 207 776 1219 Nomura Code (Joint Broker)     Notes to Editors: About Medgenics: Medgenics is a commercial -stage biopharmaceutical company developing its unique tissue-based Biopump platform technology to provide sustained-action protein therapy for the treatment of a range of chronic diseases. The first revenue generating commercial deal with a well known multinational pharmaceutical company was negotiated in late 2009. Biopumps are made using needle biopsies taken from the lower layer of the patient's skin under local anaesthetic, and processed during 10-14 days to become 30 mm long tissue biofactories producing the required protein.  The requisite number of Biopumps are injected under the patient's skin to provide sustained protein production and delivery for many months. The Compan

RNS Number : 1815N Medgenics Inc 07 June 2010    Medgenics, Inc. ('Medgenics' or the 'Company')   Statement re. Share Price Movement   Medgenics (AIM: MEDG and MEDU), the company that has developed a novel technology for the manufacture and delivery of therapeutic proteins continuously in patients using their own tissue, has noted the significant share price movement and recent press coverage in both the MEDU and MEDG quotes.   The Company confirms that it is not aware of any unpublished price sensitive information or of any other reason for the recent share price movements.   For further information, contact:   Andrew Pearlman                                              +972 4 902 8900 CEO Medgenics, Inc   Mike Wort / Anna Dunphy                                 +44 207 861 3838 De Facto Communications (PR)   James Pinner / Derek Crowhurst                        +44 207 444 0800 Religare Capital Markets (Nomad)                       Ian Callaway / Alex Mattey                               +44 207 638 5600 SVS Securities plc (Joint Broker)   Jonathan Senior                                                 +44 207 776 1219 Nomura Code (Joint Broker)     Notes to Editors: About Medgenics: Medgenics is a commercial -stage biopharmaceutical company developing its unique tissue-based Biopump platform technology to provide sustained-action protein therapy for the treatment of a range of chronic diseases. The first revenue generating commercial deal with a well known multinational pharmaceutical company was negotiated in late 2009. Biopumps are made using needle biopsies taken from the lower layer of the patient's skin under local anaesthetic, and processed during 10-14 days to become 30 mm long tissue biofactories producing the required protein.  The requisite number of Biopumps are injected under the patient's skin to provide sustained protein production and delivery for many months. The Compan

http://www.screencast.com/users/globalcrossings/folders/Jing/media/1714aa28-c59d-41d1-8c70-c833b3423cb1

http://www.screencast.com/users/globalcrossings/folders/Jing/media/762a4844-df95-494b-a69c-47aee6454511

Cheers.

To trade this must phone your broker... GLA:)

With ray?.. I hold a few shares.

This could turn out to be a very good play today..? We'll know once it starts trading online...:)

Thoroughly. http://www.screencast.com/users/globalcrossings/folders/Jing/media/6b626ecc-111a-4018-98bc-2540d4660bda

Until they both can be traded online... She could turn out to be some good fun!

Could be a interesting but risky trade today... GLA RNS Number : 1693N AIM 07 June 2010      NOTICE   (279)   07/06/2010 12:00pm   RESTORATION OF TRADING ON AIM   ASTAIRE GROUP PLC   The trading on AIM for the under-mentioned securities was temporarily suspended.  The suspension is lifted from 07/06/2010 12:00pm, an announcement having been made.     Ordinary Shares of 0.1p each fully paid (3-179-219)(GB0031792194)        If you have any queries relating to the above, please contact the company's nominated adviser 020 7598 5368.   Ref:  AIMNOT279   This information is provided by RNS The company news service from the London Stock Exchange   END     EXCLLFSIRIIDIII

For a relatively small company Vectura, the respiratory inhaler firm, has garnered a lot of attention from the broking community with its full year results, with most happy with the way things are going. FinnCap said the revenue, gross profit and loss after tax were all healthier than the broker had been forecasting. “We are encouraged by recent progress, not least the revelation that VR315 is in the regulatory phase in Europe and the confirmation of Novartis’ progress with NVA237/QVA149 which carries $157.5m in milestone payments, plus a single digit royalty on sales,” enthuses FinnCap analyst Keith Redpath, who rates the shares a “buy” with a 120p price target. “On revenues alone a 2x multiple would value Vectura at £144m (including cash) so the potential near-term royalty from VR315 and these milestones are not in the current £123m market cap,” Redpath maintains. Singer Capital Markets is also a buyer of the shares, with a target price of 101p. The broker likes the company’s attractive portfolio of products, visible revenue stream and good cash position. Singer hints that there is no need to rush to buy the shares, however. “The news flow is back end weighted for this calendar year, and shareholders could wait to buy if needed,” the broker advises. KBC Peel Hunt, meanwhile, feels the market will “welcome the toned down plans for VR315 in the US with a partnership deal still possible.” The company said it will move VR315 (generic Advair) forward in a “cost-effective manner” whilst “assessing third-party interest”. The broker rates the shares a hold, and has a target price of 45p, saying it needs “a little more information” on what the company means by ‘assessing third party interest,” though it acknowledges that the shares look better value than they did a month ago.

With a small loss, Just getting a bit impatient... Watch it will now start flying! GLA

Why did I not hold on to my ASM position last Thursday!?! I made a profit, but I should have held longer than 20 minutes!:)

...

Hmmm... I'm not familiar with CSLT, I'll have to look into it. I've not quite figured out my strategy with NPE & EO. Just need to determine how much and when to put money into both hoping to bank off of the looming Rns's... Jozi... Buys going through on the Plus Market...:)

Darling... As you know, I would not dump $$$ into a share if I did not feel there was a reasonable chance of making a few £££. Spread is 5.03-5.20p... Okay you win. It may be 45 mins. to an hour!:)lol Are you watching anything today?